<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512458605</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512458605</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Training in MS: influence of two different endurance training protocols (aquatic <italic>versus</italic> overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bansi</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512458605">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bloch</surname><given-names>W</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512458605">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gamper</surname><given-names>U</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512458605">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kesselring</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512458605">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512458605"><label>1</label>Rehabilitation, Klinik-Valens, Switzerland</aff>
<aff id="aff2-1352458512458605"><label>2</label>German Sport University Cologne, Institute of Cardiology and Sports Medicine, Germany</aff>
<author-notes>
<corresp id="corresp1-1352458512458605">Jens Bansi, Klinik-Valens, Department of Sports Therapy, CH-7317 Valens, Switzerland. Email: <email>Jens.Bansi@kliniken-valens.ch</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>5</issue>
<fpage>613</fpage>
<lpage>621</lpage>
<history>
<date date-type="received">
<day>14</day>
<month>12</month>
<year>2011</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>4</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>29</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>7</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>7</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458512458605">
<title>Background:</title>
<p>The influences of exercising on cytokine response, fatigue and cardiorespiratory values are important aspects of rehabilitation in persons with multiple sclerosis (PwMS). Exercise performed within these programs is often practised in water but the effects of immersion on PwMS have not been systematically investigated.</p>
</sec>
<sec id="section2-1352458512458605">
<title>Objective:</title>
<p>The objective of this study is to determine differences in cytokine and neurotrophin concentrations, fatigue and cardiorespiratory values in response to 3 week endurance training conducted on a cycle ergometer or an aquatic bike.</p>
</sec>
<sec id="section3-1352458512458605">
<title>Methods:</title>
<p>A randomized controlled clinical trial was conducted in 60 MS patients (Expanded Disability Status Scale range 1.0–6.5). Resting serum levels of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), Interleukin-6, soluble receptor of IL-6 and tumor necrosis factor alpha, and concentrations in response to cardiopulmonary exercise test (CPET), fatigue and cardiorespiratory values were determined at entry and discharge. Subjects performed daily 30 minute training at 60% of VO<sub>2</sub>max.</p>
</sec>
<sec id="section4-1352458512458605">
<title>Results:</title>
<p>Cytokines and neurotrophins showed no significant differences between groups over the training intervention. Within the water group BDNF resting and post-CPET concentrations (<italic>p</italic>&lt;0.05) showed a significant increase and NGF tended to increase after the training intervention. Short-term effects on BDNF (CEPT) tended to increase at the start and significantly thereafter (<italic>p</italic>&lt;0.05). No changes occurred in the land group. Other cytokines and fatigue scores remained unchanged over the training period. Cardiorespiratory values improved significantly over time within both groups.</p>
</sec>
<sec id="section5-1352458512458605">
<title>Conclusion:</title>
<p>This study indicates that aquatic training activates BDNF regulation and can be an effective training method during rehabilitation in PwMS.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Multiple sclerosis</kwd>
<kwd>aquatic therapy</kwd>
<kwd>rehabilitation</kwd>
<kwd>immersion</kwd>
<kwd>BDNF</kwd>
<kwd>NGF</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section6-1352458512458605" sec-type="intro">
<title>Introduction</title>
<p>Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) and is accompanied by varying inflammatory manifestations, demyelization and axonal loss.<sup><xref ref-type="bibr" rid="bibr1-1352458512458605">1</xref></sup> Data shows that inflammatory and neurodegenerative processes play a key role in the pathogenesis of MS. The autoimmune inflammation leads to a dysregulation in the pro-inflammatory T-helper cell 1 and anti-inflammatory T-helper cell 2 (TH1/TH2) equation and shifts towards a TH1 cytokine profile.<sup><xref ref-type="bibr" rid="bibr1-1352458512458605">1</xref><xref ref-type="bibr" rid="bibr2-1352458512458605"/>–<xref ref-type="bibr" rid="bibr3-1352458512458605">3</xref></sup> TH1 cytokines mainly secrete Interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-α), Interferon gamma (IFN-γ) and C-reactive protein (CRP), while TH2 cytokines secrete Interleukin-4 (IL-4), Interleukin-5 (IL-5), Interleukin-10 (IL-10) and Interleukin-14 (IL-14).<sup><xref ref-type="bibr" rid="bibr4-1352458512458605">4</xref>,<xref ref-type="bibr" rid="bibr5-1352458512458605">5</xref></sup> Several studies showed that significant changes in the concentrations of TH1 cytokines, in particular of IFN- γ and TNF-α, are associated with the disease course and disability status in MS.<sup><xref ref-type="bibr" rid="bibr4-1352458512458605">4</xref>,<xref ref-type="bibr" rid="bibr6-1352458512458605">6</xref></sup></p>
<p>The release of Interleukin-6 (IL-6) from the skeletal muscle during acute exercise has been described in healthy humans and elder adults and resembles inflammatory processes<sup><xref ref-type="bibr" rid="bibr7-1352458512458605">7</xref>,<xref ref-type="bibr" rid="bibr8-1352458512458605">8</xref></sup> Most training interventions in animals and healthy humans show that increased levels of fitness lead to the up-regulation of TH2 cytokines and neurotrophin secretions of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).<sup><xref ref-type="bibr" rid="bibr8-1352458512458605">8</xref></sup> Data shows connections between elevated neurotrophin concentrations and the induction of neurogenesis, neuroplasticity and the recovery of the motor and cognitive functions.<sup><xref ref-type="bibr" rid="bibr9-1352458512458605">9</xref>,<xref ref-type="bibr" rid="bibr10-1352458512458605">10</xref></sup></p>
<p>The benefits of exercise to improve cardiovascular function and reduce fatigue in people with multiple sclerosis (PwMS) are recognized as important aspects of standardized rehabilitation programs.<sup><xref ref-type="bibr" rid="bibr11-1352458512458605">11</xref>,<xref ref-type="bibr" rid="bibr12-1352458512458605">12</xref></sup> Exercise in water uses immersion through buoyancy, hydrostatical pressure, thermal impact and water resistance.<sup><xref ref-type="bibr" rid="bibr13-1352458512458605">13</xref></sup> Aquatic therapies for PwMS vary from motor learning methods with low impact on the cardiovascular system to endurance exercises.<sup><xref ref-type="bibr" rid="bibr14-1352458512458605">14</xref></sup> The main rationale is the reduction of body temperature through water temperature and prolonged training sessions.<sup><xref ref-type="bibr" rid="bibr15-1352458512458605">15</xref></sup> The thermal influence on immunological functioning is significant but few studies have performed systematic investigations.<sup><xref ref-type="bibr" rid="bibr15-1352458512458605">15</xref>,<xref ref-type="bibr" rid="bibr16-1352458512458605">16</xref></sup></p>
<p>This study determines the immune response of cytokines and neurotrophic factors, fatigue and cardiorespiratory values to 3 weeks of endurance training conducted on a cycle ergometer and an aquatic bike. Serum concentrations of BDNF, NGF, IL-6, soluble receptor of IL-6 (sIL-6R) and TNF-α were evaluated over a 3 week training intervention. We chose cytokines TNF-α, IL-6 and sIL-6R as TH1 and neurotrophins BDNF and NGF as TH2 representatives.</p>
<p>Attenuated immune responses of the subjects were hypothesized for a short- and a long-term perspective owing to the different training settings. Short-term effects resembled the immune responses to a single exercise bout through cardiopulmonary exercise test (CPET) performed at entry (t<sub>1</sub>) and discharge (t<sub>2</sub>), long-term effects resembled the effects of the 3 week training intervention.</p>
</sec>
<sec id="section7-1352458512458605" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="section8-1352458512458605">
<title>Experimental design</title>
<p>This study is a two-pronged, 3 week training intervention conducted as a randomized controlled trial. MS patients were randomized into a training group that performed cycling on an ergometer or an aquatic bike. Both groups completed 3weeks of training and were tested by CPET at t<sub>1</sub> and t<sub>2</sub>. Endurance training within both groups was supervised by independent physiotherapists, while the principal investigator conducting CPET and data analysis was masked towards the training groups. The training was set into the normal rehabilitation program which consisted of two physiotherapy and occupational therapy interventions per day and one session of neuropsychological training. Physiotherapy consisted of progressive resistance training (45 minutes) and one low intensity physiotherapeutic session (30 minutes). Occupational therapy focused on activities of daily living (ADL) functions (30 minutes). Neuropsychological training was performed daily for 30 minutes. All subjects had physician clearance, were informed about the study and gave their written consent before the study started. The study was approved through the regional scientific ethics committee (EKSG 09/118/3B). The number of recruited subjects allowed the detection of a medium effect for repeated measurements of the primary outcomes (<italic>n</italic>=25; power=80%; <italic>p</italic>=0.05) according to a power analysis (G*power version 3.1, University of Düsseldorf, Germany). The experimental design and patients included are shown in <xref ref-type="fig" rid="fig1-1352458512458605">Figure 1</xref>.</p>
<fig id="fig1-1352458512458605" position="float">
<label>Figure 1.</label>
<caption>
<p>Flowchart of experimental design and patients included.</p>
<p>CPET: cardiopulmonary exercise test; EDSS: Expanded Disability Status Scale; ELG: Ergometer Land Group; EWG: Ergometer Water Group; <italic>N</italic>: total number of subjects; <italic>n</italic>: number of subjects in the sub-sample.</p>
</caption>
<graphic xlink:href="10.1177_1352458512458605-fig1.tif"/>
</fig>
</sec>
<sec id="section9-1352458512458605">
<title>Subjects</title>
<p>All participants were inpatients for rehabilitation at the Valens Rehabilitation Center, Switzerland. 170 patients held a definite MS diagnosis (revised McDonald criteria<sup><xref ref-type="bibr" rid="bibr17-1352458512458605">17</xref></sup>) and were screened over a 9 month period (12 July 2010 to 10 April 2011) for study inclusion on the day of their clinical admission. 105 MS patients fulfilled the main study criteria of an Expanded Disability Status Scale (EDSS) score between 1.0 and 6.5. Patients underwent a general medical screening for study eligibility and were excluded if incontinence, persistent infections, cardiovascular and pulmonal diseases or immunosuppressive therapy were existent. During the study subjects were excluded if they had acute relapses or were given immunomodulating medication the day prior to CPET at t<sub>1</sub>/t<sub>2</sub>.</p>
<p>A total of 60 MS patients were eligible for inclusion and performed CPET. A concealed randomization procedure was carried out and patients were stratified to a training group, Ergometer Land Group (ELG) (<italic>n</italic>=28) or Ergometer Water Group (EWG) (<italic>n</italic>=24), according to the maximum workload achieved in the CPET (Loadmax) and the total FSMC score at baseline.<sup><xref ref-type="bibr" rid="bibr18-1352458512458605">18</xref></sup> Of 60 patients, 52 completed the study. In total eight had to be excluded (13%) during the training period. Five were given immunosuppressive therapy during the training phase, three aborted training in water due to their inability to comply with the daily time schedule of study activities. Baseline characteristics data is given in <xref ref-type="table" rid="table1-1352458512458605">Table 1</xref>.</p>
<table-wrap id="table1-1352458512458605" position="float">
<label>Table 1.</label>
<caption>
<p>Demographic data on MS disease course at baseline.</p>
</caption>
<graphic alternate-form-of="table1-1352458512458605" xlink:href="10.1177_1352458512458605-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristics</th>
<th align="left">ELG (n = 28)</th>
<th align="left">EWG (n = 24)</th>
<th align="left">p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>52 (46.7–56.3)</td>
<td>50 (44.6–55.1)</td>
<td>0.631</td>
</tr>
<tr>
<td>Gender (♂ /♀)</td>
<td>10/18</td>
<td>8/17</td>
<td>0.616</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>162 (164.4–171.2)</td>
<td>170 (164.7–174.1)</td>
<td>0.576</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>69 (64.7–73.6)</td>
<td>69 (63.4–75.6)</td>
<td>0.921</td>
</tr>
<tr>
<td>EDSS (1–6.5)</td>
<td>4.7 (4.1–5.3)</td>
<td>4.6 (4.0–5.2)</td>
<td>0.813</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512458605">
<p><bold>Note</bold>: All values are expressed as mean (95% confidence interval).</p>
</fn>
<fn id="table-fn2-1352458512458605">
<p>cm: centimetres; EDSS: Expanded Disability Status Scale; ELG: Ergometer Land Group; EWG: Ergometer Water Group; <italic>n</italic>: number of subjects in the sub sample; kg: kilograms; yrs: years.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-1352458512458605">
<title>Cardiopulmonary exercise test</title>
<p>At baseline participants performed a progressive CPET on a cycle ergometer (Ergoline 800, Germany) at t<sub>1</sub>. CPET was repeated the day prior to discharge at t<sub>2</sub>. the individual cardiopulmonary fitness level was monitored by direct and continuous measurements (breath by breath) of maximum oxygen consumption (VO<sub>2</sub>peak) by ergospirometry (PanGas CPX, Germany).</p>
<p>The exercise protocol consisted of (a) first 3 minutes at rest (no pedalling) on the cycle ergometer; (b) 3 minutes of unloaded pedalling as a warm up; (c) testing phase until the participant reached a symptom limited maximum. Workload was continuously ramp type increased by 5–10 Watts every minute to ensure 8–12 minutes of testing; (d) the final 3 minutes were unloaded pedalling to cool down. Heart rate (Polar Electro, Kempele, Finland) and blood pressure (Riva Rocci) were monitored for the last 10 seconds every 2 minutes during the test. The 10-point BORG<sup><xref ref-type="bibr" rid="bibr19-1352458512458605">19</xref></sup> scale therapy short form assessed the rate of perceived exertion (RPE) at phases (c) and (d). Peak oxygen consumption (VO<sub>2</sub>peak) was defined as the highest VO<sub>2</sub> value when the following criteria were attained: respiratory equivalent ratio (RER) &gt; 1.10; peak heart rate (HRpeak) within 10 min<sup>-1</sup> of age predicted maximum and rating of exertion (RPE &gt; 8.5). Blood samples (15ml) were drawn at rest prior to phase (a) and at the end of CPET phase (d) at t<sub>1</sub> and t<sub>2</sub>. Samples were taken in different endotoxin-free and heparinized tubes, centrifuged and immediately stored at -40°C.</p>
</sec>
<sec id="section11-1352458512458605">
<title>Endurance training</title>
<p>Endurance training in both groups consisted of physiologically defined heart rate controlled cycling at 50–60 rounds per minutes (rpm) at the lactate threshold<sup><xref ref-type="bibr" rid="bibr20-1352458512458605">20</xref></sup> (equal to 70% of HRmax or 60% VO<sub>2</sub>max). Water training was performed on the Aquarider professional™ (Nemcomed, Teningen, Germany) which is a revolution per minute scaled ergometer mounted in a pool. Pool depth was 130 cm and water temperature was held constant at 28°C. Training intensity in water was performed below thermoneutral conditions (32–34°C), letting heart rate decrease compared to equal intensities performed on land.<sup><xref ref-type="bibr" rid="bibr21-1352458512458605">21</xref>,<xref ref-type="bibr" rid="bibr22-1352458512458605">22</xref></sup> The mean training heart rate was adjusted according to Schnitzer et al.<sup><xref ref-type="bibr" rid="bibr23-1352458512458605">23</xref></sup> by subtracting seven beats (min<sup>-1</sup>) from the training heart rate range determined during CPET. A training session lasted 30 minutes, with the first and the last 2 minutes being the warm up and cool down phases. Weekly training sessions totalled five.</p>
</sec>
<sec id="section12-1352458512458605">
<title>Fatigue assessment</title>
<p>Fatigue was assessed with the multidimensional FSMC scale before CPET under resting conditions. FSMC has defined cut-off scores to classify mildly, moderately and severely fatigued patients. Cut-off for fatigue is set for the total score at 43 and for the motoric and cognitive sub-scores at 22. The scale has a proven test-retest liability and has been translated into multiple languages.<sup><xref ref-type="bibr" rid="bibr18-1352458512458605">18</xref></sup> Patients included in the study showed severe motor and cognitive fatigue and had no scores below the cut-off points.</p>
</sec>
<sec id="section13-1352458512458605">
<title>Blood sampling and biochemical assays</title>
<p>Blood samples were obtained by vein puncture from the antecubital vein in a seated position before the exercise bout and straight after reaching VO<sub>2</sub>peak during cool down, with the patient still seated on the ergometer. Blood samples were centrifuged at 3000 g for 10 minutes at 4°C and the supernantant was stored at -40°C until analysis was carried out after a maximum of 3 months. Cytokine protein levels were measured using a multiplexed particle-based flow cytometric cytokine assay.<sup><xref ref-type="bibr" rid="bibr24-1352458512458605">24</xref></sup> Analysis was conducted using a conventional flow cytometer (Guava EasyCyte Plus, Millipore, Zug, Switzerland) and performed with one determination for each sample. Detection limits of the measured cytokines were 0.1 pg/ml for TNF-α and IL-6, 6.0 pg/ml for sIL-6R, 0.2 pg/ml for NGF and 7.0 pg/ml for BDNF. Human cytokine kits for NGF-b were purchased from BioRad (Ismaning, Germany), for IL-6 and TNF-α from R&amp;D Systems (Oxon, UK), and for BDNF and sIL-6R from Millipore (Zug, Switzerland). The procedures closely followed the manufacturer’s instructions.</p>
</sec>
<sec id="section14-1352458512458605">
<title>Statistical analysis</title>
<p>Long- and short-term changes of immune mediated values under rest and exercise were evaluated over a 3 week training period.</p>
<p>Primary outcomes were short- (CPET) and long-term (a 3 week training intervention) changes of cytokines and neurotrophic factors. All other measures were secondary outcomes.</p>
<p>At baseline group differences for the demographic characteristics and EDSS were compared with the <italic>t</italic>-test for independent samples, gender was compared with the χ<sup>2</sup>-test. Due to the limitations caused by the distribution and high variability, short- and long-term effects were analyzed with a nonparametric Wilcoxon test for dependent samples. Group differences at baseline (t<sub>1</sub>), after the training period (t<sub>2</sub>) and for the absolute changes between t<sub>1</sub> and t<sub>2</sub> were compared with the Mann–Whitney <italic>U</italic>-test for independent samples. A 2×2 ANOVA for repeated measurements analyzed the group and time effects and interactions between time*group of the secondary outcomes.</p>
<p>The level of significance was set at 5% (<italic>p</italic>&lt;0.05). Data is presented in the figures and tables using mean and 95% confidence intervals (CI). All statistical calculations were conducted with the Statistical Package of Social Sciences version 19.0 for Mac (SPSS Inc, Chicago, USA).</p>
</sec>
</sec>
<sec id="section15-1352458512458605" sec-type="results">
<title>Results</title>
<p>Demographic values, MS disease course, primary outcomes and their differences at baseline are presented for both training groups in <xref ref-type="table" rid="table1-1352458512458605">Table 1</xref>.</p>
<p><xref ref-type="table" rid="table2-1352458512458605">Table 2</xref> summarizes the long-term changes of primary outcomes at baseline and the short-term changes in <xref ref-type="table" rid="table3-1352458512458605">Table 3</xref>. <xref ref-type="table" rid="table4-1352458512458605">Table 4</xref> shows the secondary outcomes at baseline.</p>
<table-wrap id="table2-1352458512458605" position="float">
<label>Table 2.</label>
<caption>
<p>Primary outcomes – long-term changes of the assessed variables between baseline (t<sub>1</sub>) and discharge (t<sub>2</sub>) after 3 weeks RCT.</p>
</caption>
<graphic alternate-form-of="table2-1352458512458605" xlink:href="10.1177_1352458512458605-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Value</th>
<th align="left">Group</th>
<th/>
<th align="left" colspan="2">Time point<hr/></th>
<th align="left" rowspan="2">Absolute change between t1 - t2</th>
<th align="left">p value<xref ref-type="table-fn" rid="table-fn4-1352458512458605">*</xref></th>
</tr>
<tr>
<th/>
<th/>
<th/>
<th align="left">t1</th>
<th align="left">t2</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="4">BDNF (pg/ml)</td>
<td rowspan="2">EWG</td>
<td>Rest</td>
<td>14522.1 (10232.0–18812.2)</td>
<td>17909.2 (12481.1–23337.3)</td>
<td>3387.1 (−593.4–7367.6)</td>
<td>0.046<xref ref-type="table-fn" rid="table-fn4-1352458512458605">*</xref></td>
</tr>
<tr>
<td>CPET</td>
<td>16520.1 (12506.2–20534.0)</td>
<td>22428.2 (15873.4–28983.0)</td>
<td>5908,0 (1759.3–10056.7)</td>
<td>0.010<xref ref-type="table-fn" rid="table-fn4-1352458512458605">*</xref></td>
</tr>
<tr>
<td rowspan="2">ELG</td>
<td>Rest</td>
<td>19410.4 (13548.1–25272.7)</td>
<td>19592.8 (14808.9–24376.7)</td>
<td>182,4 (−3185.7–3550.6)</td>
<td>0.699</td>
</tr>
<tr>
<td>CPET</td>
<td>17138.1 (12475.5–21800.8)</td>
<td>20551.5 (15724.3–25378.7)</td>
<td>3413.4 (6.4–6820.3)</td>
<td><bold>(0.088)</bold></td>
</tr>
<tr>
<td rowspan="4">NGF (pg/ml)</td>
<td rowspan="2">EWG</td>
<td>Rest</td>
<td>14.5 (−11.4–40.4)</td>
<td>3.5 (−1.0–8.0)</td>
<td>−11.0 (−32.5–10.5)</td>
<td><bold>(0.087)</bold></td>
</tr>
<tr>
<td>CPET</td>
<td>14.9 (−10.6–40.5)</td>
<td>3.5 (0.0–6.9)</td>
<td>−11.4 (−33.7–10.8)</td>
<td>0.837</td>
</tr>
<tr>
<td rowspan="2">ELG</td>
<td>Rest</td>
<td>1.5 (0.5–2.5)</td>
<td>1.5 (0.7–2.2)</td>
<td>0.0 (−0.6–0.5)</td>
<td>0.721</td>
</tr>
<tr>
<td>CPET</td>
<td>2.1 (−0.3–4.4)</td>
<td>2.3 (0.2–4.3)</td>
<td>0.2 (−0.7–1.0)</td>
<td>0.911</td>
</tr>
<tr>
<td rowspan="4">TNF-α (pg/ml)</td>
<td rowspan="2">EWG</td>
<td>Rest</td>
<td>6.7 (3.4–10.0)</td>
<td>7.9 (1.6–14.1)</td>
<td>1.2 (−4.1–6.5)</td>
<td>0.263</td>
</tr>
<tr>
<td>CPET</td>
<td>10.5 (3.6–17.4)</td>
<td>9.3 (3.2–15.4)</td>
<td>−1.2 (−8.6–6.1)</td>
<td>1.000</td>
</tr>
<tr>
<td rowspan="2">ELG</td>
<td>Rest</td>
<td>10.2 (5.4–14.9)</td>
<td>10.1 (5.7–14.5)</td>
<td>−0.1 (−4.9–4.7)</td>
<td>0.955</td>
</tr>
<tr>
<td>CPET</td>
<td>11.4 (6.2–16.6)</td>
<td>10.6 (5.6–15.6)</td>
<td>−0.8 (−6.3–4.7)</td>
<td>0.374</td>
</tr>
<tr>
<td rowspan="4">IL6 (pg/ml)</td>
<td rowspan="2">EWG</td>
<td>Rest</td>
<td>10.2 (−6.3–26.6)</td>
<td>5.9 (−3.0–14.8)</td>
<td>−4.3 (−12.1–3.6)</td>
<td>0.394</td>
</tr>
<tr>
<td>CPET</td>
<td>3.3 (1.0–5.6)</td>
<td>4.2 (0.0–8.4)</td>
<td>0.9 (−2.6–4.3)</td>
<td>0.761</td>
</tr>
<tr>
<td rowspan="2">ELG</td>
<td>Rest</td>
<td>4.8 (−1.5–11.2)</td>
<td>1.8 (0.6–2.9)</td>
<td>−3.0 (−9.4–3.3)</td>
<td>0.790</td>
</tr>
<tr>
<td>CPET</td>
<td>2.8 (−0.3–5.8)</td>
<td>2.5 (0.8–4.2)</td>
<td>−0.3 (−3.9–3.3)</td>
<td>0.367</td>
</tr>
<tr>
<td rowspan="4">sIL-6r [pg/ml]</td>
<td rowspan="2">EWG</td>
<td>Rest</td>
<td>31109.3 (24321.0–37897.6)</td>
<td>29989.7 (24546.0–35433.3)</td>
<td>−1119.6 (−5519,4–3280,1)</td>
<td>0.954</td>
</tr>
<tr>
<td>CPET</td>
<td>30176.5 (23436.0–36917.0)</td>
<td>30976.3 (25315.4–36637.3)</td>
<td>799,8 (−3816,1–5415,7)</td>
<td>0.470</td>
</tr>
<tr>
<td rowspan="2">ELG</td>
<td>Rest</td>
<td>36003.5 (30548.7–41458.3)</td>
<td>34576.9 (29503.7–39650.1)</td>
<td>−1426,6 (−7318,5–4465,4)</td>
<td>0.439</td>
</tr>
<tr>
<td>CPET</td>
<td>35909.2 (31177.4–40641.1)</td>
<td>35657.3 (30876.3–40438.4)</td>
<td>−251,9 (−4507,0–4003,2)</td>
<td>0.820</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512458605">
<p>Note: All values are expressed as mean (95% confidence interval).</p>
</fn>
<fn id="table-fn4-1352458512458605">
<p>BDNF: brain-derived neurotrophic factor; CPET: serum levels in response to cardiopulmonary exercise test; ELG: Ergometer Land Group; EWG: Ergometer Water Group; IL-6: Interleukine-6; ml: millilitres; NGF: nerve growth factor; pg: picograms; rest: resting serum levels; sIL-6R: soluble receptor of IL-6; t<sub>1</sub>: time point 1; t<sub>2</sub>: time point 2; TNF-α: tumor necrosis factor alpha; *: level of significance (<italic>p ≤</italic> 0.05) for the Wilcoxon test for repeated measurements.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-1352458512458605" position="float">
<label>Table 3.</label>
<caption>
<p>Primary outcomes – short-term changes of the assessed variables between resting condition and CPET at baseline (t<sub>1</sub>) and after (t<sub>2</sub>) 3 week training period.</p>
</caption>
<graphic alternate-form-of="table3-1352458512458605" xlink:href="10.1177_1352458512458605-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Value</th>
<th align="left">Group</th>
<th align="left" colspan="2">t<sub>1</sub><hr/></th>
<th align="left" colspan="2">t<sub>2</sub><hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Change CPET t<sub>1</sub>– rest t<sub>1</sub></th>
<th align="left"><italic>p</italic> value<xref ref-type="table-fn" rid="table-fn6-1352458512458605">*</xref></th>
<th align="left">Change CPET t<sub>2</sub> – rest t<sub>2</sub></th>
<th align="left"><italic>p</italic> value<xref ref-type="table-fn" rid="table-fn6-1352458512458605">*</xref></th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF (pg/ml)</td>
<td>EWG</td>
<td>1998.0 (−1034.3–5030.4)</td>
<td>0.097</td>
<td>4519.0 (1627.6–7410.4)</td>
<td>0.002</td>
</tr>
<tr>
<td/>
<td>ELG</td>
<td>−2272.3 (−5273.8–729.3)</td>
<td>0.202</td>
<td>958.7 (−2650.3–4567.6)</td>
<td>0.585</td>
</tr>
<tr>
<td>NGF (pg/ml)</td>
<td>EWG</td>
<td>0.4 (−0.8–1.7)</td>
<td>0.627</td>
<td>0.0 (−1.2–1.2)</td>
<td>0.126</td>
</tr>
<tr>
<td/>
<td>ELG</td>
<td>0.6 (−0.9–2.0)</td>
<td>0.966</td>
<td>0.8 (−0.7–2.3)</td>
<td>0.764</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>EWG</td>
<td>3.8 (−1.6–9.2)</td>
<td>0.523</td>
<td>1.4 (−0.7–3.5)</td>
<td>0.346</td>
</tr>
<tr>
<td/>
<td>ELG</td>
<td>1.2 (−3.3–5.8)</td>
<td>0.316</td>
<td>0.5 (−5.9–6.9)</td>
<td>0.909</td>
</tr>
<tr>
<td>IL6 (pg/ml)</td>
<td>EWG</td>
<td>−6.9 (−22.2–8.5)</td>
<td>0.693</td>
<td>−1.7(−6.7–3.3)</td>
<td>0.291</td>
</tr>
<tr>
<td/>
<td>ELG</td>
<td>−2.0 (−5.5–1.4)</td>
<td>0.461</td>
<td>0.7 (−0.7–2.1)</td>
<td>0.190</td>
</tr>
<tr>
<td>sIL-6r (pg/ml)</td>
<td>EWG</td>
<td>−932.8 (−7321.1–5455.5)</td>
<td>0.841</td>
<td>986.7 (−4271.4–6244.7)</td>
<td>0.361</td>
</tr>
<tr>
<td/>
<td>ELG</td>
<td>−94.3 (−4138.3–3949.8)</td>
<td>0.891</td>
<td>1080.4 (−l3747.2–5908.1)</td>
<td>0.539</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1352458512458605">
<p>Note: All values are expressed as mean (95% confidence interval).</p>
</fn>
<fn id="table-fn6-1352458512458605">
<p>BDNF: brain-derived neurotrophic factor; CPET: serum levels in response to cardiopulmonary exercise test; ELG: Ergometer Land Group; EWG: Ergometer Water Group; IL-6: Interleukine-6; ml: millilitres; NGF: nerve growth factor; pg: picograms; Rest: resting serum levels; sIL-6R: soluble receptor of IL-6; t<sub>1</sub>: time point 1; t<sub>2</sub>: time point 2; TNF-α: tumor necrosis factor alpha; *: level of significance (<italic>p ≤</italic> 0.05) for the Wilcoxon test for repeated measurements.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table4-1352458512458605" position="float">
<label>Table 4.</label>
<caption>
<p>Secondary outcomes - cardiorespiratory measures, FSMC total, motor and cognitive sub-scores and BORG scales over 3 week training intervention; results of ANOVA (main effect time, group and time*group interaction).</p>
</caption>
<graphic alternate-form-of="table4-1352458512458605" xlink:href="10.1177_1352458512458605-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="left" colspan="3">Time point<hr/></th>
<th align="left" colspan="3">ANOVA <italic>p</italic> values<hr/></th>
</tr>
<tr>
<th align="left">Value</th>
<th align="left">Group</th>
<th align="left">t<sub>1</sub></th>
<th align="left">t<sub>2</sub></th>
<th align="left">Change t<sub>2</sub>–t<sub>1</sub></th>
<th align="left">Time</th>
<th align="left">Group</th>
<th align="left">Time* Group</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="2">Loadmax (W)</td>
<td>EWG</td>
<td>62.3 (47.3–74.7)</td>
<td>74.6 (59.2–90.0)</td>
<td>12.3 (8.3–16.3)</td>
<td rowspan="2">0.000</td>
<td rowspan="2">0.289</td>
<td rowspan="2">0.574</td>
</tr>
<tr>
<td>ELG</td>
<td>72.5 (57.4–87.6)</td>
<td>86.5 (71.8–101.2)</td>
<td>14.0 (9.4–18.6)</td>
</tr>
<tr>
<td rowspan="2">VO<sub>2</sub> peak (ml/(kg<sup>−1</sup> x min<sup>−1</sup>))</td>
<td>EWG</td>
<td>17.1 (14.6–19.6)</td>
<td>18.8 (16.3–21.2)</td>
<td>1.7 (0.7–2.7)</td>
<td rowspan="2">0.000</td>
<td rowspan="2">0.572</td>
<td rowspan="2">0.988</td>
</tr>
<tr>
<td>ELG</td>
<td>18.1 (15.7–20.5)</td>
<td>19.7 (17.2–22.3)</td>
<td>1.7 (0.6–2.7)</td>
</tr>
<tr>
<td rowspan="2">HRpeak (beats min<sup>1</sup>)</td>
<td>EWG</td>
<td>126.8 (119.2–134.4)</td>
<td>135.3 (125.6–145.1)</td>
<td>8.5 (2.5–14.6)</td>
<td rowspan="2">0.005</td>
<td rowspan="2">0.486</td>
<td rowspan="2">0.158</td>
</tr>
<tr>
<td>ELG</td>
<td>134.1 (124.1–144.0)</td>
<td>137.0 (126.4–147.7)</td>
<td>3.0 (−2.3–8.3)</td>
</tr>
<tr>
<td rowspan="2">BORG</td>
<td>EWG</td>
<td>5.9 (4.9–6.8)</td>
<td>5.8 (5.0–6.5)</td>
<td>−0.1 (−1.1–1.0)</td>
<td rowspan="2">0.805</td>
<td rowspan="2">0.143</td>
<td rowspan="2">0.668</td>
</tr>
<tr>
<td>ELG</td>
<td>6.3 (5.7–6.8)</td>
<td>6.5 (5.8–7.2)</td>
<td>0.2 (−0.7–1.2)</td>
</tr>
<tr>
<td rowspan="2">FSMC total score</td>
<td>EWG</td>
<td>61.9 (55.1–68.7)</td>
<td>61.3 (55.1–67.4)</td>
<td>−0.7 (−4.1–2.7)</td>
<td rowspan="2">0.387</td>
<td rowspan="2">0.040</td>
<td rowspan="2">0.625</td>
</tr>
<tr>
<td>ELG</td>
<td>70.8 (65.3–76.4)</td>
<td>68.4 (62.5–74.4)</td>
<td>−2.4 (−8.4–3.6)</td>
</tr>
<tr>
<td rowspan="2">FSMC motor functions</td>
<td>EWG</td>
<td>33.8 (30.9–36.8)</td>
<td>33.9 (35.6–42.7)</td>
<td>0.0 (−2.2–2.3)</td>
<td rowspan="2">0.211</td>
<td rowspan="2">0.041</td>
<td rowspan="2">0.199</td>
</tr>
<tr>
<td>ELG</td>
<td>39.1 (35.6–42.7)</td>
<td>36.2 (33.3–39.1)</td>
<td>−2.9 (−6.8–1.0)</td>
</tr>
<tr>
<td rowspan="2">FSMC cognitive functions</td>
<td>EWG</td>
<td>28.2 (23.5–32.8)</td>
<td>28.1 (24.1–32.2)</td>
<td>0.0 (−2.5–2.4)</td>
<td rowspan="2">0.726</td>
<td rowspan="2">0.141</td>
<td rowspan="2">0.691</td>
</tr>
<tr>
<td>ELG</td>
<td>31.6 (28.4–34.9)</td>
<td>32.3 (28.4–36.2)</td>
<td>0.7 (−2.0–3.4)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1352458512458605">
<p>Note: All values are expressed as mean (95% confidence interval).</p>
</fn>
<fn id="table-fn8-1352458512458605">
<p>CPET: cardiopulmonary exercise test; ELG: Ergometer Land Group; EWG: Ergometer Water Group; HRpeak: maximum heart rate achieved in CPET; kg: kilograms; Loadmax: maximum workload achieved in CPET; LT: lactate threshold; ml: millilitre; min: minutes; <italic>n</italic>: number of sub-population; t<sub>1</sub>: time point 1; t<sub>2</sub>: time point 2; VO<sub>2</sub>: oxygen consumption; VO<sub>2</sub>peak: maximum oxygen consumption during CPET; W: watt; <italic>p</italic> values: refer to the level of significance (<italic>p</italic> &lt; .05) of 2×2 ANOVA for repeated measurements.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section16-1352458512458605">
<title>Effects of 3 weeks of training on the cytokine and neurotrophin values</title>
<p>Serum levels of cytokines and neurotrophins showed no significant group differences under rest and post-CPET (short-term) at t<sub>1</sub> and t<sub>2</sub>. sIL-6R showed a significant difference (<italic>p</italic>=0.046) between groups for the resting condition at baseline.</p>
<sec id="section17-1352458512458605">
<title>Short-term effects</title>
<p>For BDNF in the EWG, a significant difference of 4519.0 pg/l (95% CI -1627.6–7410.4; <italic>p</italic>=0.002) between resting and CPET were found for t<sub>2</sub>. Also, in the EWG for t<sub>1</sub>, BDNF showed a statistical trend (difference 1998.0 pg/ml; 95% CI–1034.3-5030.4; <italic>p</italic>=0.097). Other cytokine and neurotrophin values showed no effects.</p>
</sec>
<sec id="section18-1352458512458605">
<title>Long-term effects</title>
<p>Resting BDNF serum levels increased significantly over the training intervention by 3387 pg/ml (95% CI -593.4–7367.6; <italic>p</italic>=0.046) in EWG but showed no significant change in ELG. In the EWG only, BDNF concentrations increased significantly over time by 5908 pg/ml (95% CI 1759.3–10056.7; <italic>p</italic>=0.010) under CPET. In contrast, BDNF concentrations in ELG remained unchanged. A statistical trend could be shown for the NGF serum level in the EWG under rest (difference -11.0 pg/ml; 95% CI -32.5–10.5; <italic>p</italic>=0.087). Other cytokine and neurotrophin values remained unchanged. BDNF changes in resting levels and in response to CPET over the training intervention are shown in <xref ref-type="fig" rid="fig2-1352458512458605">Figure 2</xref>.</p>
<fig id="fig2-1352458512458605" position="float">
<label>Figure 2.</label>
<caption>
<p>Short- and long-term changes of BDNF resting levels and concentrations in response to CPET.</p>
<p>Data show absolute values between t<sub>1</sub> and t<sub>2</sub> for each group and condition (rest and CPET)</p>
<p>* refers to the <italic>p</italic> values of the long-term changes, ** refers to the <italic>p</italic> values of the short-term changes with the level of significance set at <italic>p</italic> &lt; 0.05 for the Wilcoxon test for repeated measurements.</p>
<p>Error bars represent mean and 95% confidence interval.</p>
<p>BDNF: brain derived neurotrophic factor; CPET: cardiopulmonary exercise test; RCT: randomized controlled trial test; t<sub>1</sub>: time point 1; t<sub>2</sub>: time point 2.</p>
</caption>
<graphic xlink:href="10.1177_1352458512458605-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section19-1352458512458605">
<title>Effects of 3 weeks of training on the fatigue scores (FSMC)</title>
<p>All patients showed severe motor (37±9) and cognitive (30±10) fatigue at baseline (FSMC total 67±16) and remained severely fatigued over the training intervention. There was no significant time effect for FSMC. A significant group effect was found for the FSMC total (<italic>p</italic>=0.040) and the motor function sub-score (<italic>p</italic>=0.041). Values of the FSMC total score were lower in EWG before and after CPET than in the ELG. In EWG, the FSMC motor function sub-score showed lower values at t<sub>1</sub> and higher values at t<sub>2</sub> compared to ELG. There was no time*group interaction, indicating that there were no significant differences in the gradient between both training groups.</p>
<p>Changes of the FSMC scores are shown in <xref ref-type="table" rid="table4-1352458512458605">Table 4</xref>.</p>
</sec>
<sec id="section20-1352458512458605">
<title>3.3 Effects of 3 weeks of training on cardiorespiratory values</title>
<p>Loadmax and VO<sub>2</sub>peak showed significant time effects over the 3 weeks training period in both training groups (<italic>p</italic>&lt;0.001). Loadmax increased by 12.3 W (95%CI 8.3–16.3) in EWG and by 14.0 W (95%CI 9.4–18.6) in ELG .VO<sub>2</sub>peak showed a significant time effect (<italic>p</italic>&lt;0.001). In EWG, VO<sub>2</sub>peak increased by 1.7 ml / (kg<sup>-1</sup> × min<sup>- 1</sup>) (95%CI 0.7–2.7), in ELG VO<sub>2</sub>peak also increased by 1.7 ml / (kg<sup>-1</sup> × min<sup>- 1</sup>) (95%CI 0.6–2.7).</p>
<p>The HRpeak showed a significant time effect (<italic>p</italic>&lt;0.005). Under immersion the HRpeak increased in EWG by 8.5 1/min<sup>-1</sup> (95%CI 2.5–14.8) and in ELG by 3.0 1/min<sup>-1</sup> (95%CI -2.3–8.3).</p>
<p>Cardiorespiratory values showed no significant differences between the groups and there were no significant time*group effects. Changes in the cardiorespiratory response over the 3 week training intervention are shown in <xref ref-type="table" rid="table4-1352458512458605">Table 4</xref>.</p>
</sec>
</sec>
<sec id="section21-1352458512458605" sec-type="discussion">
<title>Discussion</title>
<p>These results indicate that immersion can affect the immune function of PwMS. Given the differences in training settings, BDNF concentrations were activated in the EWG and showed significant short- and long-term changes. Without immersion equal training settings showed no effects. Improvements to cardiorespiratory fitness were attained within both groups, although patients remained fatigued. These findings are beneficial effects while water training has not been systematically studied in PwMS.</p>
<sec id="section22-1352458512458605">
<title>4.1 Cytokine and neurotrophin response</title>
<p>The short- and long-term effects of endurance training on neurotrophins (BDNF and NGF) and pro-inflammatory cytokines (IL-6, sIL-6R and TNF-α) were assessed in different training settings. Both short- and long-term effects indicate an attenuated immune response for immersion compared to equal overland training. Short-term effects produced a significant difference between rest and CPET at t<sub>2</sub>, indicating a higher immune reactivity. There were long-term effects only in EWG with significantly higher BDNF serum levels, indicating that training produced an adaption of the immune system.</p>
<p>The increased BDNF levels in EWG may be an indication of induced anti-inflammatory influences through immersion.<sup><xref ref-type="bibr" rid="bibr14-1352458512458605">14</xref></sup> Several studies investigated the influences of immersion on endocrine reactions in normal trained subjects.<sup><xref ref-type="bibr" rid="bibr25-1352458512458605">25</xref>,<xref ref-type="bibr" rid="bibr26-1352458512458605">26</xref></sup> They conclude that immersed conditions led to lower adrenalin and noradrenalin serum concentrations compared to equal intensities performed on land. This indicates that immersion dampens sympathetic pathway activity and further dominates parasympathetic influences, with a consequent up-regulation of anti-inflammatory proliferations. Associations between pro-inflammatory cytokines and the hyperactivity of the HPA axis have been described in psychiatric patients with mood disorders<sup><xref ref-type="bibr" rid="bibr27-1352458512458605">27</xref></sup> and lately in the MS pathology.<sup><xref ref-type="bibr" rid="bibr28-1352458512458605">28</xref></sup></p>
<p>The absence of a BDNF increase in ELG coincides with the results of Gold et al.<sup><xref ref-type="bibr" rid="bibr29-1352458512458605">29</xref></sup> and Schulz et al.<sup><xref ref-type="bibr" rid="bibr30-1352458512458605">30</xref></sup> They conclude that 8 weeks of moderate ergometer cycling is not capable of attaining elevated BDNF concentrations in MS subjects.</p>
</sec>
<sec id="section23-1352458512458605">
<title>Fatigue response</title>
<p>The data shows no improvements in fatigue on the total FSMC scores within both training groups, the subjects remained severely fatigued after the training intervention, although data from former studies indicates that increased fitness through endurance training has the potential to improve fatigue.<sup><xref ref-type="bibr" rid="bibr31-1352458512458605">31</xref><xref ref-type="bibr" rid="bibr32-1352458512458605"/><xref ref-type="bibr" rid="bibr33-1352458512458605"/><xref ref-type="bibr" rid="bibr34-1352458512458605"/>–<xref ref-type="bibr" rid="bibr35-1352458512458605">35</xref></sup></p>
<p>Two other studies exercised pre-fatigued PwMS at baseline. Both showed no significant effects on fatigue scores, although participants tolerated training intensities and improved levels of fitness.<sup><xref ref-type="bibr" rid="bibr12-1352458512458605">12</xref>,<xref ref-type="bibr" rid="bibr32-1352458512458605">32</xref></sup></p>
<p>Former studies applied an exercise frequency of 2 days a week during 8–12 weeks.<sup><xref ref-type="bibr" rid="bibr29-1352458512458605">29</xref>,<xref ref-type="bibr" rid="bibr30-1352458512458605">30</xref>,<xref ref-type="bibr" rid="bibr32-1352458512458605">32</xref>,<xref ref-type="bibr" rid="bibr34-1352458512458605">34</xref>,<xref ref-type="bibr" rid="bibr35-1352458512458605">35</xref></sup> Only one study performed daily training sessions.<sup><xref ref-type="bibr" rid="bibr12-1352458512458605">12</xref></sup> Patients in this study were recruited from a rehabilitative stay with a mean duration of 3 weeks and daily training which may have caused subjects to remain fatigued. Fatigue scores in this study differed at baseline within both groups, this may have affected the results in favour of EWG.</p>
</sec>
<sec id="section24-1352458512458605">
<title>Cardiorespiratory response</title>
<p>The exercise intensities were well tolerated by all participants and although fatigued showed improvements of cardiorespiratory functions. This provides further evidence that endurance training improves exercise performance even if patients are severely fatigued.<sup><xref ref-type="bibr" rid="bibr12-1352458512458605">12</xref>,<xref ref-type="bibr" rid="bibr32-1352458512458605">32</xref></sup> The improvements of cardiorespiratory fitness levels were more pronounced under immersion and resembles the main rationale that justifies aquatic therapies to reduce body temperature and enable PwMS to prolong their training sessions. Thus, the observed benefits may be a consequence of exposure to cooler water temperatures (cooling effect)<sup><xref ref-type="bibr" rid="bibr36-1352458512458605">36</xref></sup> and additionally shows decreased concentrations of stress hormones through induced regeneration processes.<sup><xref ref-type="bibr" rid="bibr25-1352458512458605">25</xref>,<xref ref-type="bibr" rid="bibr26-1352458512458605">26</xref></sup></p>
<p>Previous studies investigated thermal influences on cardiac responses and have shown a dependence of training heart rate and water temperature.<sup><xref ref-type="bibr" rid="bibr22-1352458512458605">22</xref>,<xref ref-type="bibr" rid="bibr23-1352458512458605">23</xref></sup> Schnitzer et al.<sup><xref ref-type="bibr" rid="bibr23-1352458512458605">23</xref></sup> conclude that a general correction of the training heart rate is not justified when training is performed at thermalneutral conditions (31–33°C) but should be applied if training sessions are performed below 31°C. They recommend reductions of 3–4 beats at 30°C, 6–7 beats at 28°C and 8–9 beats at 26°C. Water temperature was held at 28°C and the training heart rate range was adjusted by seven beats.</p>
</sec>
<sec id="section25-1352458512458605">
<title>Study limitations</title>
<p>There are several limitations to be taken into account. First, not all participants in the EWG attained complete immersion. With a fixed pool depth at 130 cm, standardized immersion with the waterline at the xiphisternum was not achieved and limited the impact on the database. Second, primary outcomes show high variations and cytokine sIL-6R shows baseline differences. Third, in FSMC total and motor sub-score groups showed baseline differences which could have confounded the results in favour of EWG. Fourth, the achieved heart rates in CPET were peak values as CPET ended at the subjective felt maximum of the participant. The attained effects have to be seen as learning and conditioning effects towards the test procedures.</p>
</sec>
<sec id="section26-1352458512458605">
<title>Conclusion</title>
<p>This study indicates that exercising under immersion can activate BDNF regulation of PwMS compared to overland training. Aquatic training can be effective during rehabilitation in PwMS inducing anti-inflammatory proliferations. Future research is required to clarify the impacts of immersion during exercise on cytokine and neurotrophin production.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>The authors wish to thank Nemcomed©, Germany, for lending the Rehabilitation Center Valens two aqua bikes over the training period and U. Dalgas for his comments on the manuscript. The laboratory tests were analyzed through the excellent expertise of A. Urwyler, Cytolab, Switzerland.</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research was supported by Biogen-Dompe (nr. BD_09_212), CH-6300, Switzerland.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512458605">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brück</surname><given-names>W</given-names></name>
</person-group>. <article-title>Inflammatory demyelination is not central to the pathogenesis of multiple scleosis</article-title>. <source>J Neurol</source> <year>2005</year>; <volume>252</volume>: <fpage>10</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512458605">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lucchinetti</surname><given-names>C</given-names></name>
<name><surname>Brück</surname><given-names>W</given-names></name>
<name><surname>Parisi</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination</article-title>. <source>Ann Neurol</source> <year>2000</year>; <volume>47</volume>: <fpage>707</fpage>–<lpage>717</lpage></citation>
</ref>
<ref id="bibr3-1352458512458605">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heesen</surname><given-names>C</given-names></name>
</person-group>. <article-title>Endocrine and cytokine responses to standardized physical stress in multiple sclerosis</article-title>. <source>Brain Behav Immun</source> <year>2003</year>; <volume>17</volume>: <fpage>473</fpage>–<lpage>481</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512458605">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Von Boxel-Dezaire</surname><given-names>AH</given-names></name>
<name><surname>Hoff</surname><given-names>SC</given-names></name>
<name><surname>van Oosten</surname><given-names>BW</given-names></name>
<etal/>
</person-group>. <article-title>Decreased Interleukin 10 and increased interleukin 12p40 mRNA are associated with decreased activity and characterize different disease stage in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>1999</year>; <volume>45</volume>: <fpage>695</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512458605">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hohlfeld</surname><given-names>R</given-names></name>
<name><surname>Kerschensteiner</surname><given-names>M</given-names></name>
<name><surname>Stadelmann</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis</article-title>. <source>J Neuroimmunol</source> <year>2000</year>; <volume>107</volume>: <fpage>161</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512458605">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keegan</surname><given-names>BM</given-names></name>
<name><surname>Noseworthy</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Multiple Sclerosis</article-title>. <source>Annu Rev Med</source> <year>2002</year>; <volume>53</volume>: <fpage>285</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512458605">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pedersen</surname><given-names>AM</given-names></name>
<name><surname>Petersen</surname><given-names>BK</given-names></name>
</person-group>. <article-title>The anti-inflammatory effects of exercise</article-title>. <source>J Appl Physiol</source> <year>2005</year>; <volume>98</volume>: <fpage>1154</fpage>–<lpage>1162</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512458605">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kohut</surname><given-names>M</given-names></name>
<name><surname>McCann</surname><given-names>D</given-names></name>
<name><surname>Russell</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Aerobic exercise, but not flexibility/resistance exercise, reduces serum IL-18, CRP, and IL-6independent of [beta]-blockers, BMI, and psychosocial factors in older adults</article-title>. <source>Brain Behav Immun</source> <year>2006</year>; <volume>20</volume>: <fpage>201</fpage>–<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512458605">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Castellano</surname><given-names>V</given-names></name>
<name><surname>White</surname><given-names>L</given-names></name>
</person-group>. <article-title>Serum brain-derived neurotrophic factor response to aerobic exercise in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2008</year>; <volume>269</volume>: <fpage>85</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512458605">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prakash</surname><given-names>RS</given-names></name>
<name><surname>Snook</surname><given-names>EM</given-names></name>
<etal/>
</person-group>. <article-title>Aerobic fitness is associated with gray matter volume and white matter integrity in multiple sclerosis</article-title>. <source>Brain Res</source> <year>2010</year>; <volume>1341</volume>: <fpage>41</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512458605">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andreasen</surname><given-names>AK</given-names></name>
<name><surname>Stanager</surname><given-names>E</given-names></name>
<name><surname>Dalgas</surname><given-names>U</given-names></name>
</person-group>. <article-title>The effect of exercise on fatigue in multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1041</fpage>–<lpage>1054</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512458605">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mostert</surname><given-names>S</given-names></name>
<name><surname>Kesselring</surname><given-names>J</given-names></name>
</person-group>. <article-title>Effects of a short term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2002</year>; <volume>8</volume>: <fpage>161</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512458605">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kamioka</surname><given-names>H</given-names></name>
<name><surname>Tsutani</surname><given-names>K</given-names></name>
<name><surname>Okuizumi</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Effectiveness of aquatic exercise and balneotherapy: a summary of systematic reviews based on randomized controlled trials of water immersion therapies</article-title>. <source>J Epidemiol</source> <year>2010</year>; <volume>20</volume>: <fpage>2</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512458605">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wiesner</surname><given-names>S</given-names></name>
<name><surname>Birkenfeld</surname><given-names>AL</given-names></name>
<name><surname>Engeli</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Neurohumoral and metabolic response to exercise in water</article-title>. <source>Horm Metab Res</source> <year>2010</year>; <volume>42</volume>: <fpage>334</fpage>–<lpage>339</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512458605">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roehrs</surname><given-names>TG</given-names></name>
<name><surname>Karst</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Effects of an aquatics exercise program on quality of life measures for individuals with progressive multiple sclerosis</article-title>. <source>J Neurol Phys Ther</source> <year>2004</year>; <volume>28</volume>: <fpage>63</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512458605">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gehlsen</surname><given-names>GM</given-names></name>
<name><surname>Grigsby</surname><given-names>SA</given-names></name>
<name><surname>Winant</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Effects of an aquatic fitness program on the muscle strength and endurance of patients with multiple sclerosis</article-title>. <source>Phys Ther</source> <year>1984</year>; <volume>31</volume>: <fpage>653</fpage>–<lpage>657</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512458605">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Ednan</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”</article-title>. <source>Ann Neurol</source> <year>2005</year>; <volume>58</volume>: <fpage>840</fpage>–<lpage>846</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512458605">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Penner</surname><given-names>IK</given-names></name>
<name><surname>Raseli</surname><given-names>C</given-names></name>
<name><surname>Stocklin</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>The Fatigue Scale for Motor and Cognitive functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>1509</fpage>–<lpage>1517</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512458605">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Borg</surname><given-names>G</given-names></name>
</person-group>. <article-title>Psychophysical bases of perceived exertion</article-title>. <source>Med Sci Sports Exerc</source> <year>1982</year>; <volume>14</volume>: <fpage>377</fpage>–<lpage>81</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512458605">
<label>20.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Wassermann</surname><given-names>K</given-names></name>
<name><surname>Hansen</surname><given-names>JE</given-names></name>
<name><surname>Sue</surname><given-names>DY</given-names></name>
<etal/>
</person-group>. <source>Principles of exercise testing and prescription</source>. <edition>4th ed.</edition> <publisher-loc>Philadelphia</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>, <year>2005</year>.</citation>
</ref>
<ref id="bibr21-1352458512458605">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilcock</surname><given-names>IM</given-names></name>
<name><surname>Cronin</surname><given-names>JB</given-names></name>
<name><surname>Hing</surname><given-names>WA</given-names></name>
</person-group>. <article-title>Physiological response to water immersion: a method for sport recovery?</article-title> <source>Sports Med</source> <year>2006</year>; <volume>36</volume>: <fpage>747</fpage>–<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512458605">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>KS</given-names></name>
<name><surname>Choi</surname><given-names>JK</given-names></name>
<name><surname>Park</surname><given-names>YS</given-names></name>
</person-group>. <article-title>Cardiovascular regulation during water immersion</article-title>. <source>Appl Human Sci</source> <year>1999</year>; <volume>18</volume>: <fpage>233</fpage>–<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512458605">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schnitzer</surname><given-names>W</given-names></name>
<name><surname>Fenzl</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Concerning a question about the correction of the training heart rate in the water. Significance of the water temperature?</article-title> <source>Phys Med Rehab Kuror</source> <year>2006</year>; <volume>16</volume>: <fpage>330</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512458605">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vignali</surname><given-names>DA</given-names></name>
</person-group>. <article-title>Multiplexed particle-based flow cytometric assays</article-title>. <source>J Immunol Methods</source> <year>2000</year>; <volume>243</volume>: <fpage>243</fpage>–<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512458605">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Krishna</surname><given-names>G</given-names></name>
<name><surname>Danovitch</surname><given-names>GM</given-names></name>
<name><surname>Sowers</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Catecholamine responses to central volume expansion produced by head-out water immersion and saline infusion</article-title>. <source>J Clin Endocrinol Metab</source> <year>1983</year>; <volume>56</volume>: <fpage>998</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512458605">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grossman</surname><given-names>E</given-names></name>
<name><surname>Goldstein</surname><given-names>DS</given-names></name>
<name><surname>Hoffman</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Effects of water immersion on sympathoadrenal and dopa-dopamine systems in humans</article-title>. <source>Am J Physiol</source> <year>1992</year>; <volume>262</volume>: <fpage>R993</fpage>–<lpage>R999</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512458605">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>SM</given-names></name>
<name><surname>Krüger</surname><given-names>S</given-names></name>
<name><surname>Ziegler</surname><given-names>KJ</given-names></name>
<etal/>
</person-group>. <article-title>Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis with comorbid major depression</article-title>. <source>J Neurol Nuerosurg Psychiatry</source> <year>2011</year>; <volume>82</volume>: <fpage>814</fpage>–<lpage>818</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512458605">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heesen</surname><given-names>C</given-names></name>
<name><surname>Romberg</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Physical exercise in multiple sclerosis: supportive care or a putative disease- modifying treatment</article-title>. <source>Expert Rev Neurotherap</source> <year>2006</year>; <volume>6</volume>: <fpage>347</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512458605">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gold</surname><given-names>SM</given-names></name>
<name><surname>Schulz</surname><given-names>KH</given-names></name>
<name><surname>Hartmann</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Basal serum levels reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized exercise in multiple sclerosis and controls</article-title>. <source>J Neurol Sci</source> <year>2003</year>; <volume>138</volume>: <fpage>99</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512458605">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schulz</surname><given-names>KH</given-names></name>
<name><surname>Gold</surname><given-names>SM</given-names></name>
<name><surname>Witte</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2004</year>; <volume>225</volume>: <fpage>11</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512458605">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dalgas</surname><given-names>U</given-names></name>
<name><surname>Stenager</surname><given-names>E</given-names></name>
<name><surname>Jacobson</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Fatigue, mood and quality of life improve in MS patients after progressive resistance training</article-title>. <source>Mult Scler</source> <year>2010</year>; <volume>16</volume>: <fpage>480</fpage>–<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512458605">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Surraka</surname><given-names>J</given-names></name>
<name><surname>Romberg</surname><given-names>A</given-names></name>
<name><surname>Ruutiainen</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Effects of aerobic and strength exercise on motor fatigue in men and women with multiple sclerosis: a randomized controlled trial</article-title>. <source>Clin Rehabil</source> <year>2004</year>; <volume>18</volume>: <fpage>737</fpage>–<lpage>746</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512458605">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rasova</surname><given-names>K</given-names></name>
<name><surname>Havrdova</surname><given-names>E</given-names></name>
<name><surname>Brandejsky</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of the influence of different rehabilitation programmes on clinical, spirometric and spiroergometric parameters in patients with multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2006</year>; <volume>12</volume>: <fpage>227</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512458605">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cakt</surname><given-names>BD</given-names></name>
<name><surname>Nacir</surname><given-names>B</given-names></name>
<name><surname>Genc</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Cycling progressive resistance training for people with multiple sclerosis: a randomized controlled study</article-title>. <source>Am J Phys Med Rehabil</source> <year>2010</year>; <volume>89</volume>: <fpage>446</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512458605">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Romberg</surname><given-names>A</given-names></name>
<name><surname>Virtanen</surname><given-names>A</given-names></name>
<name><surname>Ruutiainen</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study</article-title>. <source>Neurology</source> <year>2004</year>; <volume>63</volume>: <fpage>2034</fpage>–<lpage>2038</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512458605">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beenakker</surname><given-names>EA</given-names></name>
<name><surname>Oparina</surname><given-names>TI</given-names></name>
<name><surname>Hartgring</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Cooling garment treatment in MS: clinical improvement and decrease in leukocyte NO production</article-title>. <source>Neurology</source> <year>2001</year>; <volume>57</volume>: <fpage>892</fpage>–<lpage>894</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>